No significant elevation of any of these metabolites was detected in the plasma of the FH carrier group in comparison with the control NC group (no FH carriers) or the FH-WT RCC samples, supporting a lack of a dominant negative effect on patients’ plasma metabolites (Figure 8E). The gene discussed is FH; the disease is renal cell carcinoma.